Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -52% Improvement Relative Risk Song et al. NCT04415086 COOP-COVID-19-MCTI Conv. Plasma RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? RCT 129 patients in Brazil (June - November 2020) Higher mortality with convalescent plasma (not stat. sig., p=0.37) Song et al., The Lancet Regional Health - Americas, doi:10.1016/j.lana.2022.100216 Favors conv. plasma Favors control

Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)

Song et al., The Lancet Regional Health - Americas, doi:10.1016/j.lana.2022.100216, COOP-COVID-19-MCTI, NCT04415086 (history)
Song et al., Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard.., The Lancet Regional Health - Americas, doi:10.1016/j.lana.2022.100216, COOP-COVID-19-MCTI, NCT04415086
Jun 2022   Source   PDF  
  All Studies   Meta
RCT 129 severe COVID-19 patients in Brazil, showing no significant difference in outcomes with convalescent plasma.
risk of death, 51.7% higher, RR 1.52, p = 0.37, treatment 22 of 87 (25.3%), control 7 of 42 (16.7%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Song et al., 30 Jun 2022, Randomized Controlled Trial, Brazil, peer-reviewed, median age 61.0, 20 authors, study period 2 June, 2020 - 18 November, 2020, average treatment delay 8.0 days, trial NCT04415086 (history) (COOP-COVID-19-MCTI).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)
Alice T W Song, Vanderson Rocha, Alfredo Mendrone-Júnior, Rodrigo T Calado, Gil C De Santis, Bruno D Benites, Carolina Costa-Lima, Taiani Vargas, Leonardo S Marques, Juliana C Fernandes, Felipe C Breda, Silvano Wendel, Roberta Fachini, Luiz V Rizzo, José Mauro Kutner, Vivian I Avelino-Silva, Rafael R G Machado, Edison L Durigon, Sylvie Chevret, Esper G Kallas
The Lancet Regional Health - Americas, doi:10.1016/j.lana.2022.100216
Background Administration of convalescent plasma may serve as an adjunct to supportive treatment to prevent COVID-19 progression and death. We aimed to evaluate the efficacy and safety of 2 volumes of intravenous convalescent plasma (CP) with high antibody titers for the treatment of severe cases of COVID-19. Methods We conducted a Bayesian, randomized, open-label, multicenter, controlled clinical trial in 7 Brazilian hospitals. Adults admitted to hospital with positive RT-PCR for SARS-CoV2, within 10 days of the symptom onset, were eligible. Patients were randomly assigned (1:1:1) to receive standard of care (SoC) alone, or in combination with 200 mL (150−300 mL) of CP (Low-volume), or 400 mL (300−600 mL) of CP (High-volume); infusion had to be performed within 24 h of randomization. Randomization was centralized, stratified by center. The primary outcome was the time until clinical improvement up to day 28, measured by the WHO ten-point scale, assessed in the intention-to-treat population. Interim and terminal analyses were performed in a Bayesian framework. Trial registered at NCT04415086.
TV, LSM, JCF, CSL, and FCB led the implementation of the study. SC did the statistical plan and analysis and SC, ATWS, VIAS, NBC, and DGA have verified the underlying data. RRGM, ELD, CPS, RM, DBA, CSL, and EDC generated laboratory data. ATWS, VR, SC, VIAS, and EGK drafted the report. All other authors contributed to the implementation and data collection. All authors reviewed and approved the final report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. Supplementary materials Supplementary material associated with this article can be found in the online version at doi:10.1016/j. lana.2022.100216.
Abani, Abbas, Abbas, Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial, The Lancet
Avendaño-Sol A, Inez, Muñez-Rubio, A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia, J Clin Invest
B Egin, Callum, Jamula, Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial, Nat Med, doi:10.1038/s41591-021-01488-2
Bar, Shaw, Choi, A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia, J Clin Invest
Berry, Bayesian clinical trials, Nat Rev Drug Discov
Casadevall, Henderson, Joyner, SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities, J Clin Invest
Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med
Cheng, Wong, Soo, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis
Gharbharan, Jordans, Geurtsvankessel, Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection, Nat Commun
Hamilton, Lee, Arnold, Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial, Int J Infect Dis
Harrell, Lindsell, Statistical design and analysis plan for sequential parallel-group RCT for COVID-19
Horby, Mafham, Recovery, Group, RECOVERY): a randomised, controlled, openlabel, platform trial, doi:10.1101/2021.06.15.21258542
Hung, To, Lee, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection, Clin Infect Dis
Hung, To, Lee, Hyperimmune IV immunoglobulin treatment, Chest
Joyner, Bruno, Klassen, Safety update, Mayo Clin Proc
Joyner, Carter, Senefeld, Convalescent plasma antibody levels and the risk of death from Covid-19, N Engl J Med
Korley, Durkalski-Mauldin, Yeatts, Early convalescent plasma for high-risk outpatients with Covid-19, N Engl J Med
Kunze, Johnson, Van Helmond, Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors, Nat Commun
K€ Orper, Weiss, Zickler, Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19, J Clin Invest
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and lifethreatening COVID-19: a randomized clinical trial, JAMA
Libster, Erez Marc, Wappner, Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med
Marshall, Murthy, Diaz, A minimal common outcome measure set for COVID-19 clinical research, Lancet Infect Dis
Matthay, Thompson, Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties, Lancet Respir Med
Menichetti, Popoli, Puopolo, Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial, JAMA Netw Open
O'donnell, Grinsztejn, Cummings, A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19, J Clin Invest
Ryan, Bruce, Metcalfe, Using Bayesian adaptive designs to improve phase III trials: a respiratory care example, BMC Med Res Methodol, doi:10.1186/s12874-019-0739-3
Salazar, Christensen, Graviss, Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality, Am J Pathol
Santos, Proença, Leal, Marra, Yokoyama et al., References 1 WHO Coronavirus (COVID-19) dashboard
Sekine, Arns, Fabro, Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial, Eur Respir J
Simonovich, Pratx, Scibona, A Randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med
Tworek, Jaro N K, Uszy Nska-Ka»u_ Za, Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients − propensity-score matched case-control study, Int J Infect Dis
Van Griensven, Edwards, De Lamballerie, Evaluation of convalescent plasma for Ebola virus disease in Guinea, N Engl J Med
Von Cube, Schumacher, Wolkewitz, Causal inference with multistate models-estimands and estimators of the population attributable fraction, J R Stat Soc Ser A Stat Soc
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Zhou, Zhong, Guan, Treatment with convalescent plasma for influenza A (H5N1) infection, N Engl J Med
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop